文献速递糖尿病

恩格列净在肾移植后糖尿病受者中的疗效与安全性

Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.
PubMed 文献 · Diabetes Care · 2019-03-12

结果显示恩格列净组糖化血红蛋白中位变化显著优于安慰剂组(-0.2% vs 0.1%,P=0.025),并伴随体重显著下降(-2.5 kg vs 1.0 kg,P=0.014),不良事件、免疫抑制剂水平及eGFR组间无显著差异。

要点

  • 恩格列净10mg每日一次治疗24周可显著降低肾移植后糖尿病受者的HbA1c。
  • 恩格列净组体重下降2.5kg,安慰剂组增加1.0kg,组间差异显著。
  • 不良事件、免疫抑制剂血药浓度及eGFR在两组间无显著差异。

核心结论

  • 恩格列净在肾移植后糖尿病受者中表现出安全性,并较安慰剂改善血糖控制。
  • 治疗同时伴随体重下降。

研究设计与样本

  • 受者随机接受恩格列净10mg每日一次或安慰剂治疗24周。
  • 纳入标准为移植时间>1年、诊断肾移植后糖尿病、肾功能稳定(eGFR>30 mL/min/1.73 m2)且免疫抑制方案稳定。

主要发现

  • 恩格列净组HbA1c中位变化为-0.2%(-0.6,-0.1)[-2.0 mmol/mol(-6.5,-1.0)],安慰剂组为0.1%(-0.1,0.4)[1.0 mmol/mol(-0.75,3.8)],组间P=0.025。
  • 血糖下降幅度取决于GFR和基线HbA1c。
  • 恩格列净组体重变化为-2.5 kg(-4.0,-0.05),安慰剂组为1.0 kg(0.0,2.0),组间P=0.014。
  • 两组在不良事件、免疫抑制剂药物水平或eGFR方面无显著差异。

临床怎么用

  • 对于肾功能稳定(eGFR>30 mL/min/1.73 m2)且免疫抑制方案稳定的肾移植后糖尿病受者,可考虑使用恩格列净10mg每日一次以改善血糖并减轻体重。
  • 治疗期间需关注不良事件、免疫抑制剂水平及eGFR,但本研究中未见组间显著差异。

局限性

  • 随访时间较短(24周),长期疗效与安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have lately become the recommended treatment in patients with type 2 diabetes and high cardiovascular risk. Patients with posttransplant diabetes mellitus (PTDM) also have high cardiovascular risk. The aim of this study was to investigate the safety and efficacy of empagliflozin in renal transplant recipients with PTDM. RESEARCH DESIGN AND METHODS: Forty-nine renal transplant recipients were included in an investigator-initiated, single-center, prospective, double-blind study and randomized to receive either 10 mg empagliflozin or placebo once daily for 24 weeks. Patients transplanted >1 year ago, diagnosed with PTDM, with stable renal function (estimated glomerular filtration rate [eGFR] >30 mL/min/1.73 m2), and with stable immunosuppressive therapy were studied. RESULTS: Forty-four renal transplant recipients (22 empagliflozin/22 placebo, 34 males) completed the study. Median (interquartile range) change in glycated hemoglobin (HbA1c) was significantly reduced with empagliflozin compared with placebo: -0.2% (-0.6, -0.1) (-2.0 mmol/mol [-6.5, -1.0]) vs. 0.1% (-0.1, 0.4) (1.0 mmol/mol [-0.75, 3.8]) (P = 0.025). The magnitude of glucose reduction was dependent on GFR and baseline HbA1c. The treatment also resulted in a significant reduction in body weight of -2.5 kg (-4.0, -0.05) compared with an increase of 1.0 kg (0.0, 2.0) in the placebo group (P = 0.014). There were no significant differences between the groups in adverse events, immunosuppressive drug levels, or eGFR. CONCLUSIONS: Empagliflozin appeared safe and improved glycemic control in renal transplant recipients with PTDM compared with placebo. A concomitant reduction in body weight was seen.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes Care. 2019. PMID: 30862658. doi:10.2337/dc19-0093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。